Merck: FDA approves IM route of administration for MMRV family of vaccines

Merck announced that the U.S. FDA has approved the addition of the intramuscular route of administration to the United States Product Insert for Merck’s MMRV family of vaccines: M-M-R II, VARIVAX, and ProQuad. While these vaccines have a long history in the U.S., until now they have only been administered via subcutaneous injection. Additionally, the MMRV family of vaccines has already been licensed for IM administration in the European Union.